Umbilical vein graft

Figure 2.8 Infrared spectrography illustrating a normal lipid pattern (blackened areas) in the upper left panel and a similar normal pattern from a graft retrieved from a patient who expired from unrelated causes 34months following implantation. These patterns demonstrate the small amount of lipid located within these grafts. The bottom panels illustrate massive lipid accumulation in the umbilical vein graft in patients who expired from atherosclerotic disease at 8 months in the left panel and 42 months in the right panel.

Figure 2.9 Critical surface tension (CST) values between 20 and 25 d per square centimeter are favorable for providing a thrombo-resistant surface. This figure illustrates a satisfactory CST of an umbilical vein graft flow surface after having been retrieved eight months following implantation. Textiles and prosthetics tend to have higher CSTs.

Figure 2.10 Radiograph of an umbiUcal vein graft extending to the pophteal artery in the left panel but because of a very poor runoff, an additional umbilical vein graft was used as a sequential graft from the original femoral pophteal bypass to the anterior tibial artery (right panel).

Giordano JM, Keshishian JM. Aneurysm formation in human umbilical vein grafts. Surgery 1982 91 343-5. 

Haun WE, Brantigan CO, Sawyer RB. Intimal breakdown causing failure of human umbilical vein graft. Arch Surg 1981 116 230-1. 

Allograft Homograft. Transplanted vascular graft tissues derived from the same species as recipient. Example glutaraldehyde treated umbilical cord vein graft... 

Ultra high molecular weight polyethylene Linear thermoplastics with very high molecular weight (>2 X 10 g/mol) used for orthopedic devices such as acetabular cup for hip joint replacement. Umbilical cord vein grafts Vascular graft made from umbdical cord veins. 

Dardik H, Miller N, Dardik A, et al. A decade of experience with the glutaraldehyde-tanned human umbilical cord vein graft for revascularization of the lower limb. J Vase Surg 1988 7 336 6. 

Dardik H, Wengerter K, Qin F, Pangilinan A, Silvestri F, Wolodiger F, et al. Comparative decades of experience with glutaraldehyde-tanned human umbilical cord vein graft for lower limb revascularization an analysis of 1275 cases. J Vase Surg 2002 35 64-71. 

Johnson WC, Lee KK, et al. A comparative evaluation of polytetrafluoroethylene, umbilical vein, and saphenous vein bypass grafts for femoral-popliteal above-knee revascularization a prospective randomized Department of Veterans Affairs cooperative study. J Vase Surg 2000 32 268-77. 

Layer GT, King RB, Jamieson CW. Early aneurysmal degeneration of human umbilical vein bypass grafts. Br J Surg 1984 71 709-10. 

Roedersheimer LR, Feins RH, Schwartz SI, DeWeese JA, Green RM. Comparison of platelet adherence and aggregation in modified human umbilical vein and autogenous vein grafts. Am 7 Swrg 1980 140 591-5. 

Ammonia plasma treatment was combined with FN grafting to modify PHBHHx surface for possible application in vascular tissue engineering. The results demonstrated a better growth of human umbilical vein endothelial cells (HUVECs) and rabbit aorta smooth muscle cells (SMCs) on the surface of ammonia plasma-treated PHBHHx coated with FNcompared with the FN-coated or uncoated PHBHHx [45]. 

In terms of graft patency, a large prospective randomized Veterans Affairs Cooperative study (33) compared human umbilical vein with ePTFE and autogenous saphenous vein for lower extremity bypass. For patients in whom a bypass was performed for limb salvage (critical ischemia), 5-year cumulative assisted primary patency rates for human umbilical vein were 53%, which was better than the ePTFE rate of 37%... 

Umbilical cord vein grafts, 44-13 Unequal anisotropy ratios, 21-6 Uniform convergence, 23-14 Uniform volume of infinite extent, monopole and dipole fields, 20-3-20-4 Units per contact and per... 

---